Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Deferred Tax Assets (2020 - 2024)

Vistagen Therapeutics (VTGN) has disclosed Current Deferred Tax Assets for 5 consecutive years, with $74000.0 as the latest value for Q1 2024.

  • Quarterly Current Deferred Tax Assets rose 10.45% to $74000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $74000.0 through Mar 2024, up 10.45% year-over-year, with the annual reading at $74000.0 for FY2024, 10.45% up from the prior year.
  • Current Deferred Tax Assets hit $74000.0 in Q1 2024 for Vistagen Therapeutics, down from $74500.0 in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $133500.0 in Q1 2021 to a low of $67000.0 in Q3 2022.
  • Historically, Current Deferred Tax Assets has averaged $99513.3 across 5 years, with a median of $116900.0 in 2020.
  • Biggest five-year swings in Current Deferred Tax Assets: increased 14.2% in 2021 and later tumbled 49.81% in 2022.
  • Year by year, Current Deferred Tax Assets stood at $116900.0 in 2020, then grew by 14.2% to $133500.0 in 2021, then crashed by 49.81% to $67000.0 in 2022, then rose by 11.19% to $74500.0 in 2023, then decreased by 0.67% to $74000.0 in 2024.
  • Business Quant data shows Current Deferred Tax Assets for VTGN at $74000.0 in Q1 2024, $74500.0 in Q4 2023, and $74500.0 in Q3 2023.